Registered title, quoted from ClinicalTrials.gov
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 8 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 9
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteNanchang People's HospitalNanchangHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
- Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
- Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07745257, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 80 years; sex: women only
Registered eligibility fields
histologically or cytologically documented HR+/HER2- breast cancer
Inclusion criterion 4
No more than 3 lines of prior systemic therapy for advanced disease
Inclusion criterion 9
No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting
Inclusion criterion 10
No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months
Inclusion criterion 11
Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment
Inclusion criterion 13
Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia
Exclusion criterion 3
ECOG PS of 0-1
Inclusion criterion 2
Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07745257, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Women aged ≥ 18 years
- ECOG PS of 0-1
- Life expectancy of at least 12 weeks
- histologically or cytologically documented HR+/HER2- breast cancer
- radiologically confirmed brain parenchymal metastases without the need for immediate local therapy
- measurable brain metastasis lesion according to RANO-BM criteria
- Must have active brain metastases, defined as newly diagnosed brain metastases or progressive brain metastases following prior local therapy
- Prior systemic therapy must meet all the following criteria:
- No more than 3 lines of prior systemic therapy for advanced disease
- No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting
- No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months
- Adequate hematological, hepatic and renal function
- Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment
- Patients must be able to participate and comply with treatment and follow-up
Exclusion Criteria:
- Patients with leptomeningeal metastases, brainstem metastases or skull metastases
- Prior receipt of anti-angiogenic agents or Culmerciclib
- Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia
- Patients with visceral crisis,defined as severe organ dysfunction assessed by symptoms, signs, laboratory examinations and rapid disease progression
- Inability to swallow capsules or tablets
- Any severe and/or uncontrolled medical disease
- Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma
- Radiographic evidence of tumor invasion of major vessels, or high risk of tumor invasion into major vessels resulting in life-threatening hemorrhage as assessed by the investigator
- Patients with arterial or venous thromboembolic events within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism
- Participation in other anti-tumor clinical trials within 4 weeks prior to enrollment
- Any other condition that the investigator considers inappropriate to participate in this trial
Quoted from ClinicalTrials.gov, NCT07745257, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07745257, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.